Chromogenic In Situ Hybridization-Reference-Cited by-同舟云学术

Chromogenic In Situ Hybridization

Published:2009-10-01 Issue:4 Volume:132 Page:514-520
ISSN:1943-7722
Container-title:American Journal of Clinical Pathology
language:en
Short-container-title:

Author:

Bartlett J.M.S.¹²,Campbell Fiona M.¹,Ibrahim Merdol²,Wencyk Peter³,Ellis Ian³,Kay Elaine⁴,Connolly Yvonne⁵,O’Grady Anthony⁴,Di Palma Silvana⁶,Starczynski Jane⁷,Morgan John M.⁸,Jasani Bharat⁹,Miller Keith²

Affiliation:

1. Endocrine Cancer Group, Edinburgh, Scotland

2. UK National External Quality Assessment Scheme, University College London, London, England

3. Department of Histopathology, Nottingham City Hospital, Nottingham, England

4. Department of Histopathology, Beaumont Hospital, Dublin, Ireland

5. Adelaide and Meath Hospital, Dublin, Ireland

6. Department of Histopathology, the RSCH, University of Surrey, Guildford, England

7. Birmingham Heartlands Hospital, Birmingham, England

8. Department of Histopathology, Cardiff & Vale NHS Trust, Cardiff, Wales

9. Department of Pathology, School of Medicine, Cardiff University, Cardiff, Wales

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

http://academic.oup.com/ajcp/article-pdf/132/4/514/24987178/ajcpath132-0514.pdf

Reference17 articles.

1. HER2 testing in the UK: further update to recommendations;Walker;J Clin Pathol,2008

2. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer;Wolff;J Clin Oncol,2007

3. Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy;Bartlett;Am J Pharmacogenomics,2005

4. Predictive markers in breast cancer: the future;Faratian;Histopathology,2008

5. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme;Bartlett;J Clin Pathol,2007

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Medicine in Cytopathology;Surgical Pathology Clinics;2024-09

2. Recent Advances in Molecular Diagnostic Techniques for Breast Cancer Detection;PROG BIOCHEM BIOPHYS;2020

3. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?;Virchows Archiv;2019-04-05

4. The Human Epidermal Growth Factor Receptor 2 (HER2) as a Prognostic and Predictive Biomarker: Molecular Insights into HER2 Activation and Diagnostic Implications;Cancer Prognosis;2018-12-05

5. Comparison of HER2 status determination methods in HER2 (2 +) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH);Annals of Diagnostic Pathology;2017-12